# GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.

Source: https://onco.cc/trials/nct06558773/  
OnCo record `nct06558773` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of regorafenib in colorectal cancer, run by Chinese PLA General Hospital, now recruiting.

## Summary

GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. is a phase 2, randomised interventional study registered as NCT06558773 by Chinese PLA General Hospital, with a registry enrolment figure of 120 participants, started 2026-03-01 and due to reach its primary completion in 2027-03-01. Interventions recorded: Regorafenib+Immune checkpoint inhibitor; Eliglustat+Immune checkpoint inhibitor; Eliglustat+Immune checkpoint inhibitor +Regorafenib. Conditions listed: Colorectal Cancer. Primary outcome: Objective response rate (ORR). Colorectal eligibility wording from the registry: "Histologically confirmed diagnosis of unresectable locally advanced, recurrent or metastatic colorectal cance have failed at least two lines of prior treatment". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06558773
- Phase: 2
- Setting: GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor and/or Regorafenib for Patients With Advanced/Metastatic pMMR/MSS Colorectal Cancer:an Open-Label, Randomized,Phase II Study
- Sponsor: Chinese PLA General Hospital
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06558773: https://clinicaltrials.gov/study/NCT06558773

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Regorafenib](https://onco.cc/drugs/regorafenib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06558773.json